Leap Therapeutics Stock Alpha and Beta Analysis

LPTX Stock  USD 2.91  0.02  0.69%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Leap Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Leap Therapeutics over a specified time horizon. Remember, high Leap Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Leap Therapeutics' market risk premium analysis include:
Beta
1.4
Alpha
0.2
Risk
5.7
Sharpe Ratio
0.0555
Expected Return
0.32
Please note that although Leap Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Leap Therapeutics did 0.20  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Leap Therapeutics stock's relative risk over its benchmark. Leap Therapeutics has a beta of 1.40  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Leap Therapeutics will likely underperform. At this time, Leap Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price Fair Value is likely to rise to 1.41 in 2024, whereas Book Value Per Share is likely to drop 2.79 in 2024.

Enterprise Value

13.55 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Leap Therapeutics Backtesting, Leap Therapeutics Valuation, Leap Therapeutics Correlation, Leap Therapeutics Hype Analysis, Leap Therapeutics Volatility, Leap Therapeutics History and analyze Leap Therapeutics Performance.
For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Leap Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Leap Therapeutics market risk premium is the additional return an investor will receive from holding Leap Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Leap Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Leap Therapeutics' performance over market.
α0.20   β1.40

Leap Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Leap Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Leap Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Leap Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Leap Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Leap Therapeutics shares will generate the highest return on investment. By understating and applying Leap Therapeutics stock market price indicators, traders can identify Leap Therapeutics position entry and exit signals to maximize returns.

Leap Therapeutics Return and Market Media

The median price of Leap Therapeutics for the period between Thu, Sep 26, 2024 and Wed, Dec 25, 2024 is 2.9 with a coefficient of variation of 16.69. The daily time series for the period is distributed with a sample standard deviation of 0.49, arithmetic mean of 2.94, and mean deviation of 0.37. The Stock received some media coverage during the period.
 Price Growth (%)  
       Timeline  
1
Acquisition by Mashiach Nissim of 25000 shares of Leap Therapeutics at 2.45 subject to Rule 16b-3
10/02/2024
2
Disposition of 50000 shares by Jason Baum of Leap Therapeutics at 2.57 subject to Rule 16b-3
10/10/2024
3
Disposition of 2136 shares by Mirabelli Christopher of Leap Therapeutics at 2.82 subject to Rule 16b-3
11/13/2024
4
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
11/26/2024

About Leap Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Leap or other stocks. Alpha measures the amount that position in Leap Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2010 2023 2024 (projected)
Dividend Yield0.01420.002610.00248
Price To Sales Ratio88.99166.84109.75

Leap Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Leap Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Leap Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Leap Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Leap Therapeutics. Please utilize our Beneish M Score to check the likelihood of Leap Therapeutics' management manipulating its earnings.
22nd of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Leap Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.